{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"KRASCENDO 3","nct_id":"NCT07541170","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=krascendo-3-nct07541170. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"KRASCENDO 3","arms":[{"description":"Participants will receive divarasib, orally (PO), once daily (QD) for up to 52 cycles (1 cycle = 21 days).","label":"Divarasib","type":"EXPERIMENTAL"},{"description":"Participants will receive either pembrolizumab, nivolumab, or undergo observation, depending on the treatment received prior to surgery. No study treatment will be given to participants who will undergo observation.","label":"Control: Pembrolizumab or Nivolumab or Observation","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2035-03-31","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":400,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Divarasib","otherNames":["RO743584; GDC-6036"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"},{"name":"Nivolumab","otherNames":["Opdivo"],"type":"DRUG"}],"last_update":"2026-10-13","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Patients With Resected Stage II-III KRAS G12C-Positive Non-small Cell Lung Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2032-01-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-free Survival (DFS), as Determined by the Investigator","timeFrame":"From randomization to disease recurrence or death from any cause (Up to approximately 5 years)"}],"references":[],"start_date":{"date":"2026-10-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT07541170"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/krascendo-3-nct07541170"}